Swedish Orphan Biovitrum AB
(OTC: SWOBY)
|
3:21 PM UTC, 06/28/24 | |||
---|---|---|---|---|
Last: $13.58 | Change: -0.29 | %Change: -2.13% | Volume: 12,000 |
Open: | $ 13.58 | Volume: | 12,000 | |
---|---|---|---|---|
High: | $ 13.58 | Yield(%) | 0.00 | |
Low: | $ 13.58 | P/E Ratio (ttm): | 45.54 | |
Dividend ($): | 0.45 | Market Cap ($): | 9.37B | |
EPS ($) | 0.30 | Shares Out: | 679.74M |
% Price Change (last 4 weeks): | -1.43 |
---|---|
% Price Change (last 13 weeks): | 7.62 |
% Price Change (last 26 weeks): | 4.28 |
% Price Change (last 52 weeks): | -45.60 |
% Price Change (year to date): | 3.69 |
Return on Equity (%): | 7.68 |
---|---|
Return on Assets (%): | 3.66 |
Return on Invested Capital (%): | 9.55 |
Gross Profit Margin (%): | 63.52 |
---|---|
Net Profit Margin (%): | 10.89 |
Operating Profit Margin (%): | 21.05 |
|
|
50-day Moving Average: | $7.13 |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | 2,326 |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
|
Swedish Orphan Biovitrum AB
Tomtebodavägen 23A Solna AB 112 76 Phone: 46.8.697.20.00 Fax: 46.8.697.23.30 http://www.sobi.com |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | n/a |
Current P/E Ratio (ttm): | 45.54 |
Book Value ($): | 4.95 |
Cash Flow ($): | 0.77 |
Price/Earnings (x): | 45.54 |
---|---|
Price/Sales (x): | 4.16 |
Price/Book (x): | 2.69 |
Price/Cash Flow (x): | 20.58 |
Quick Ratio (x): | 0.46 |
---|---|
Current Ratio (x): | 0.66 |
LT Debt/Equity (x): | 34.03 |
Total Debt/Equity (x): | 60.49 |